跳至主要内容
临床试验/DRKS00019187
DRKS00019187尚未招募不适用

PTM-TK: Non interventional study on the implementation of quantitative determination of DRH1 antibody (AB) equivalents in serum by using the DRH1 antibody clone with PT Monitor® as part of therapy control in patients with HPV16-induced vulva- and cervical tumors - PTM-TK

Abviris Deutschland GmbH0 个研究点目标入组 200 人开始时间: 2019年12月30日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
Female

入选标准

  • 1. >18 years
  • 2. Willingness and ability to submit declaration of consent after receiving relevant information, and signed declaration of consent
  • 3. Consent to compliance with the required follow-up appointments
  • 4. Diagnosis of HPV16-induced vulva carcinoma or pre-cancer requiring treatment
  • 5. Diagnosis of an HPV16-induced cervical carcinoma or pre-cancer requiring treatment
  • 6. Positive Prevo Check® result at day of hospital admittance and positive PT Monitor® result at start of therapy t0 (= 7 days before to 7 days after initial therapeutic intervention to remove tumor)
  • 7. Therapy of HPV16-positive tumor not started before t0.

排除标准

  • 1. An operative or medical condition that would expose the patient to increased risk from the study. The investigator will make the decision based on the patient's history and/or clinical picture or lab values.
  • 2. Lack of willingness and ability to provide declaration of consent
  • 3. Patients who have been vaccinated against HPV. Patients who have been vaccinated against HPV show a positive concentration of antibodies against HPV16 L1 (equals DRH1 antibody equivalents) due to the immunisation by the vaccination
  • 4. Patients who are vaccinated against HPV during the study period
  • 5. Patients with diagnosed HPV16 tumor whose therapy has already started before the start of this study.
  • 6. Participation in a concurrent study with the exception of observational studies
  • 7. HIV-positive patients

研究者

相似试验